Duocarmycins (A, 1a; SA, 1b; B1, 1e; B2, 1c; C1, 1f; C2, 1d) are novel antitumor antibiotics isolated from the culture broth of Streptomyces sp. (Fig. 1) . [1] [2] [3] Since duocarmycins 1e, 1c, 1f, and 1d readily yield 1a 1a-c) in aqueous solution, 1a is considered to be an active form among these duocarmycins. Duocarmycins 1a and 1b have a unique cyclopropane ring responsible for the sequence-selective and reversible alkylation of double-stranded DNA mediating N3 adenine covalent adduct formation. 4) This mechanism is similar to that of CC-1065 (2a) which has been reported to show high cytotoxicity (Fig. 2) .
Some minor groove alkylators were found to be very potent cytotoxic agents. 13) In contrast, noncovalent minor groove binders exhibit only marginal antitumor activity. The representatives of these reagents are distamycin (2b) and netropsin (2c). Distamycin (2a) and netropsin (2c) bind to the minor groove, predominantly recognizing A · T-rich sequences.
13) Distamycin derivatives which bind to DNA by covalent interaction have been developed. 13b) Among the alkylating derivatives of distamycin, tallimusine (FCE 24517, 2d) has been identified and is being tested in early clinical studies. 14) Recently, Fregeau, Lown and co-workers have reported the structural features of the covalent bonding of a novel cyclopropylpyrroloindole (CPI)-lexitropsin conjugate (2e) to a model duplex DNA, which was examined by high field 1 H-NMR analysis and restrained molecular dynamics calculations.
15) The CPI-lexitropsin conjugate, which was designed for enhanced DNA binding compared with natural (ϩ)-CC-1065, exhibits an exceptional cytotoxic potency against KB human nasopharangeal tumor cells in vitro of IC 50 ϭ0.76 fg/l.
15a) The racemic CPI-lexitropsin conjugate reacted readily with the duplex oligonucleotide d(CGCAATTGCG) 2 to form a single covalent adduct as the major product.
Our goal is to design an A-ring pyrrole of duocarmycin derivatives having greater activity and/or less toxicity than that of 4Ј-methoxycinnamates which exhibited the best results in our previous studies. For this purpose, our approach is to synthesize new compounds which have 5-membered heteroarylacryloyl groups (thienylacryloyl or pyrrolylacryloyl) as Seg-B. We are interested in beneficial effects on the binding potency of the conjugated molecule to DNA by changing the 6-membered ring to a 5-membered ring. More-over, we synthesized derivatives without the double bond as a spacer in Seg-B in order to examine whether the double bond as a spacer increases anticellular and antitumor activity by enhancing noncovalent binding to the minor groove of DNA. In this paper, we report our investigation regarding the synthesis, anticellular and antitumor activities, hematotoxicity, and structure-activity relationships (SAR) of these derivatives.
Chemistry For the formation of a thienylacryloyl moiety as Seg-B parts, we first synthesized the p-nitrophenyl esters of methoxy-substituted or non-substituted thienylacrylic acid, as shown in Chart 1. The methoxy-thiophene aldehydes (7b, 16a) 7c, 16b) 7d, 16c) 7e
16d,e)
) were prepared from starting materials (3) (4) (5) (6) . Their methoxy-thienylacrylic acid ethyl esters 17) were synthesized from the methoxy-thiophene aldehydes and triethyl phosphonoacetate by a Horner-Emmons reaction.
18) The obtained methoxy-thienylacrylic acid ethyl esters were treated with 4 N KOH to yield the corresponding methoxy-thienylacrylic acid. Their p-nitrophenyl esters (8a-e) were then prepared from the corresponding methoxy-thienylacrylic acid and p-nitrophenol using the Mukaiyama reagent 19) in good yields. The 2-methyl-3-methoxycarbonyl A-ring pyrrole compound of duocarmycin (DU-86, 1g) was prepared by employing Wagner-Meerwein type rearrangement of the 8-O-protected-3-hydroxyduocarmycin B2, followed by deprotection of the protecting group under basic conditions. 12, 20) The treatment of 1g with NaOMe in MeOH provided Seg-A (9) . The obtained compound 9 was allowed to react with p-nitrophenyl thienylacrylates in the presence of NaH to yield the corresponding thienylacrylates (10a-e) in reasonable yields. 11, 12) The 8-O-[(N-methylpiperazinyl) carbonyl] derivatives were synthesized from these thienylacrylates (10a-e) as described in preceding papers, 12) in order to increase in vivo antitumor activities and their stability under various conditions. The thienylacrylates were converted to p-nitrophenyl carbonate by treatment with HBr, followed by the reaction with p-nitrophenyl chloroformate in the presence of triethylamine. The carbonates were allowed to react with the Nmethylpiperazine to produce 8-O-[(N-methylpiperazinyl) carbonyl] derivatives. The obtained 8-O-[(N-methylpiperazinyl) carbonyl] derivatives were converted to hydrochloride salts (11a-c) by the treatment with HCl in MeOH and EtOH. However, the aqueous solubility of these salts (11a-c) was found to be below 0.1 mg/ml. Though we tried the same procedure with 3Ј-thienylacrylates (10d-e), we were unable to obtain the corresponding 8-O-[(N-methylpiperazinyl) carbonyl] derivatives because of decomposition in the reaction system.
We studied those derivatives with a pyrrole skeleton in Seg-B as the other 5-membered heterocycle. Compounds 12a-f were prepared according to the method reported previously.
21) The synthesis of compound 14a was performed according to the same procedures used for 10a. Formation of the pyrrolecarboxylate analog with three N-methyl-2-pyrrolecarboxyamide units, like the distamycin molecule, was examined by coupling compound 14a and 2-pyrrolecarboxylic acids (12c, e). Compound 14a was deprotected with HBr in MeOH and ClCH 2 CH 2 Cl at 50°C and treated with saturated NaHCO 3 to give 4Ј-amino-2Ј-pyrrolecarboxylate (15) as the intermediate. 15 was condensed with 2-pyrrolecarboxylic acid (12c or 12e) by using diethyl cyanophosphonate (DECP) to give Seg-B analogs with three N-methyl-2-pyrrolecarboxyamide units (14b, c). was prepared by the reaction of 14b with HBr in CH 3 CN and MeOH, followed by the addition of acetic anhydride in the presence of 4-dimethylaminopyridine (DMAP).
The preparation of 2Ј-pyrrolylacrylates having a double bond as a spacer is outlined in Chart 3. The methyl Nmethyl-2-pyrrolecarboxylates (12a, 12d, 12f) were reduced with LiAlH 4 , followed by oxidation with MnO 2 to give the corresponding N-methyl-2-pyrrolecarboxyaldehydes. were prepared by the same method as that for the thienylacrylic acids and their p-nitrophenyl ester (see Chart 1). Although we attempted condensation with the 4Ј-amino-pyrrole compound, shown in Chart 2, it did not succeed. Compounds 19b and 19c were prepared by the reaction of 9 with 6.86 N HCl in AcOEt, followed by the addition of 17b or 17c in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) as a condensing agent. 22) Compounds 19b and 19c were then treated with 1, 8-diazabicyclo[5.4 .0]undec-7-ene (DBU) to give cyclopropane compounds 20b and 20c, respectively. To synthesize the 8-Oacetate (21a) or 8-O-[(N-methylpiperazinyl) carbonyl] derivatives (22) , preparation of the C8 phenolic hydroxyl compound with a bromomethyl group in the C-ring part was attempted by the reaction of 20a with HBr at room temperature as in previous method; 12,23a) however, compound 20a was decomposed. When the reaction temperature was lowered to Ϫ20°C, compounds 21a and 22 were obtained in high yield without decomposition. The O-acetates (21b-c) were also prepared by the same procedure as that for 16.
Results and Discussion
The anticellular activity of thienylacrylates against HeLa S 3 cells was evaluated in vitro. The thienylacrylates (10a, b, 10d, e) exhibited potent anticellular activity with IC 50 values below 3.0 nM at 72 h exposure, which were almost equivalent to compound 1h. The anticellular activity of all the carbonyl] derivatives of the thienylacrylates was about 1/100 of that of the corresponding cyclopropane derivatives. This result showed that the carbonyl] derivatives were not converted to cyclopropane derivatives as active metabolites in the culture medium.
7d,23) The antitumor activity of the carbonyl] derivatives (11a-c) against sarcoma 180 murine solid tumor was evaluated in vivo. The in vivo efficacy was expressed as T/C, which is defined as the treated versus control value of the tumor volume. Tumor volume was calculated according to the method described previously. 7, 8) Compounds 11a-c exhibited potent antitumor activity in vivo (T/C; 0.09-0.35). Compound 11b, with 4Ј-methoxy-2Ј-thienylacryloyl as Seg-B, showed more effective antitumor activity than compound 11a with 2Ј-thienylacryloyl without a methoxy moiety. This result was supported by our observation 12a) that 4Ј-methoxycinnamates exhibited the strongest anticellular activity among cinnamates. Moreover, compound 11c, in which the position of the methoxy group on the thiophene ring of Seg-B was different from 11b, showed antitumor activity inferior to 11b.
24)
On the other hand, the 2Ј-pyrrolylacrylates having a double bond as a spacer showed 10 2 -10 3 times stronger anticellular activity than 2Ј-pyrrolecarboxylates (14a vs. 20a, 14b vs. 20c ). All of the 2Ј-pyrrolylacrylates with a cyclopropane ring showed anticellular activity superior to 4Ј-methoxycinnamate (1h) (IC 50 Ͻ0.3 nM, 72 h-exposure). The 4Ј-BocNH-2Ј-pyrrolecarboxylate (14b) showed stronger anticellular activity than the 4Ј-nitro-2Ј-pyrrolecarboxylate (14c). This result was parallel to our expectation based on the strong anticellular activity of 4Ј-BocNH-cinnamates in 4Ј-substitutedcinnamates. The anticellular potency of 2Ј-pyrrolecarboxylates (14a vs. 14b) increased by the increase in the number of N-methyl pyrrolecarboxyamide units. However, the same tendency was not found in 2Ј-pyrrolylacrylates (20a vs. 20b vs. 20c) . The conversion of the 8-O-acetates to cyclopropane compounds in the culture medium resulted in strong anticellular activity below 0.3 nM, which was different from 8-O-[(N-methylpiperazinyl) carbonyl] derivatives (21a vs. 22) . carbonyl] 2Ј-pyrrolylacrylates (21a, 22) exhibited a significant antitumor effect on sarcoma 180 murine solid tumor at a lower dose compared with compound 1j. In contrast, the 8-O-acetate of 2Ј-pyrrolecarboxylate (16) exhibited no antitumor effect.
The peripheral blood toxicity (reduction of the number of peripheral blood platelets) of compound 11b, demonstrating potent antitumor activity against sarcoma 180, was lower than that of the derivatives bearing Seg-B of a natural type, and was equal to that of 4Ј-methoxycinnamates. On the other hand, 2Ј-pyrrolylacrylates showed a tendency to increase the number of peripheral blood platelets, although the reason is unclear.
We also established a simple method of investigating by HPLC whether the drug directly interacted with calf thymus DNA. 7c,8) As shown in Fig. 3 , compound 20c disappeared faster in the presence of calf thymus DNA than in its absence, while the rate of disappearance of compound 14b was less influenced by DNA. Accordingly, compound 14b had little direct interaction with calf thymus DNA, and thus showed weak anticellular activity. The double bond as a spacer is very important for strong anticellular and antitumor activity. 4Ј-Methoxycinnamate (1h) was examined by the same method. Compound 20c was similar to compound 1h. These results indicated the same tendency of anticellular activity of 20c and 1h.
Conclusions
A series of A-ring pyrrole duocarmycins bearing 5-membered heteroarylacryloyl groups were prepared and evaluted for their anticellular activity against HeLa S 3 cells, as well as antitumor activity against sarcoma 180 murine solid tumor. carbonyl] derivatives bearing 4Ј-methoxy-2Ј-thienylacryloyl as Seg-B (11b) showed remarkably potent antitumor activity and low peripheral blood toxicity in vivo compared with derivatives with the trimethoxyindole skeleton in Seg-B (1i). The 2Ј-pyrrolylacrylates with double bonds as spacers showed strong anticellular and antitumor activity superior to the 2Ј-pyrrolecarboxylates. The 8-O-acetate and the 8-O-[(N-methylpiperazinyl) carbonyl] derivatives of 2Ј-pyrrolylacrylates exhibited an antitumor effect at a lower dose compared with the 8-O-[(N-methylpiperazinyl) carbonyl] derivatives of 4Ј-methoxycinnamates. The double bond as a spacer would be very important for the strong association between the DNA minor groove and drugs.
Chart 3

Experimental
All melting points were measured on a Yanagimoto micromelting points apparatus without correction. Infrared spectra (IR) were recorded on a JASCO IR-810 spectrometer.
1 H-NMR spectra were measured on JEOL JNM-EX270 and Hitachi R-90H spectrometers. Mass spectra were measured with JEOL JMS-DX303, JMS-SX102, and Shimadzu QP-1000 spectrometers. Elemental analyses were performed with a Perkin-Elmer 2400 C, H, N analyzer. For column chromatography, silica gel (SiO 2 , Merck Kieselgel 60 F 254 ) was used. Preparative TLC (PTLC) was carried out on glass plates coated with Merck Kieselgel 60 F 254s . The usual work-up refers to washing the organic layers with brine, drying them over anhydrous Na 2 SO 4 , and evaporating off the solvents under reduced pressure.
4-Methoxy-2-thiophenecarboxaldehyde (7b) 16a) To a solution of 4-bromo-2-thiophenecarboxaldehyde (3) (2.00 g, 10.5 mmol) in EtOH (12 ml) were added NH 4 Cl (180 mg) and HC(OEt) 3 (2.61 ml, 15.7 mmol) , and the mixture was stirred at 60°C for 2 h 10 min. The reaction mixture was poured into H 2 O, and thus combination was extracted with AcOEt. The usual workup afforded 2.98 g (100%) of 2-bromo-4-thiophenecarboxaldehyde diethyl acetal. To a solution of 2-bromo-4-thiophenecarboxaldehyde diethyl acetal in MeOH (14 ml) were added CuO (150 mg), KI (21 mg) and 28 % NaOMe in MeOH (7.27 g, 37.7 mmol), and the mixture was heated in a sealed tube at 120°C for 11 h. The reaction mixture was filtered through the Celite. The filtrate was poured into 0.5 N HCl, and new mixture was extracted with AcOEt, then worked up as usual. The residue was purified by column chromatography (hexane-AcOEt, 10 : 1) to give 544 mg (67%) of 2-methoxy-4-thiophenecarboxaldehyde diethyl acetal. To a solution of 2-methoxy-4-thio- a) Drug concentration required to inhibit the growth of HeLa S 3 cells by 50%. b) Mice (5 mice/group) were implanted subcutaneously (s.c.) with tumor cells, and the drug was dosed (mg/mg) intravenously (i.v.). c) T and C are the values of the mean of tumor volume of treated and control mice, respectively. d) Number of white blood cells of tumor-bearing mice on day 4 (percent of control). e) Number of peripheral platelets of normal mice on day 7 (percent of control). f ) Not tested. g) Dose of 5.33 mg/kg. phenecarboxaldehyde diethyl acetal (496 mg, 2.29 mmol) in MeOH (10 ml) was added 4 M HCl, and the mixture was stirred at room temperature for 30 min. The reaction mixture was poured into 0.5 N HCl, and the new mixture was extracted with AcOEt. The usual work-up afforded 335 mg (100%) of 2-methoxy-4-thiophenecarboxaldehyde (7b):
1 H-NMR (90 MHz, CDCl 3 ) ␦: 9.81 (1H, s), 7.39 (1H, br s), 6.74 (1H, br s), 3.85 (3H, s) .
5-Methoxy-3-thiophenecarboxaldehyde (7e)
To a solution of 3-thiophenecarboxaldehyde (6) (1.00 g, 8.92 mmol) in CH 2 Cl 2 (30 ml) was added AlCl 3 (2.97 g, 22. 3 mmol) at room temperature for 10 min. Then, a solution of bromine (0.426 ml) in CH 2 Cl 2 (1 ml) was added to the mixture. After stirring at reflux for 1 h and 40 min, the reaction mixture was poured into H 2 O, and the new mixture was extracted with CHCl 3 . The organic layer was washed with 5% Na 2 S 2 O 3 , and worked up as usual. The residue was purified by column chromatography (hexane-AcOEt, 30 : 1) to give 1.03 g (60%) of 5-bromo-3-thiophenecarboxaldehyde.
16d) To a solution of 5-bromo-3-thiophenecarboxaldehyde (1.01 g, 5.27 mmol) in EtOH (8 ml) were added NH 4 Cl (40 mg) and HC(OEt) 3 (1.31 ml, 7.91 mmol), and the mixture was stirred at 60°C for 50 min. The reaction mixture was poured into H 2 O, and the new mixture was extracted with AcOEt. The usual work-up afforded 1.363 g (98%) of 5-bromo-2-thiophenecarboxaldehyde diethyl acetal. To a solution of 5-bromo-3-thiophenecarboxaldehyde diethyl acetal (200 mg, 0.754 mmol) in MeOH (1.5 ml) were added CuO (30 mg), KI (6.3 mg) and 28% NaOMe in MeOH (727 mg, 3.77 mmol), and the mixture was heated in a sealed tube at 120°C for 8 h and 10 min. After the addition of CuO (15 mg) and 28% NaOMe in MeOH (436 mg), the mixture was further heated in a sealed tube at 120°C for 22 h. The mixture was filtered through the Celite. Then, the filtrate was poured into 4 N HCl. After being stirred at room temperature for 20 min, the mixture was extracted with AcOEt, and worked up as usual. The residue was purified by column chromatography (hexane-AcOEt, 20 : 1-10 : 1) to give 67 mg (63%) of 5-methoxy-3-thiophenecarboxaldehyde (7e):
(E)-p-Nitrophenyl 3-(2-Thienyl)acrylate (8a) To a solution of 3-(2-thienyl)acrylic acid (7a, Aldrich) (500 mg, 3.24 mmol) in CH 2 Cl 2 (20 ml) were added p-nitrophenol (766 mg, 5.51 mmol), triethylamine (1.54 ml, 11.0 mmol) and 2-chloro-1-methylpyridinium iodide (1.41 g, 5.51 mmol), and the mixture was heated under reflux for 2 h 30 min. The reaction mixture was poured into aqueous NaHCO 3 , and the new mixture was extracted with CHCl 3 , and worked up as usual. The residue was purified by column chromatography (CHCl 3 ) to give 842 mg (94%) of (8a) 3.30; N, 5.09. Found: C, 56.99; H, 3.40; N, 5.11 .
(E)-p-Nitrophenyl 3-(4-Methoxy-2-thienyl)acrylate (8b) To a solution of 60% NaH (112 mg, 2.81 mmol) in tetrahydrofuran (THF) (2 ml) was added a solution of triethyl phosphonoacetate (630 mg, 2.81 mmol) in THF (1 ml), and the mixture was stirred under Ar atmosphere at 0°C. After 5 min, a solution of 4-methoxy-2-thiophenecarboxaldehyde (7b) (337 mg, 2.37 mmol) in THF (2 ml) was added, and the mixture was stirred at the same temperature for 1 h. The reaction was quenched by the addition of ice, and the resulting mixture was poured into 0.5 N HCl. The whole was extracted with AcOEt, and worked up as usual. The residue was purified by column chromatography (hexane-AcOEt, 15 : 1) to give 424 mg (84%) of ethyl 3-(4-methoxy-2-thienyl)acrylate. 17a) To a solution of ethyl 3-(4-methoxy-2-thienyl)acrylate (414 mg, 1.95 mmol) in MeOH (9 ml) was added 4 N KOH (1.46 ml, 5.85 mmol), and the mixture was stirred at 50°C for 1 h. The reaction mixture was poured into 0.5 N HCl, and the new mixture was extracted with AcOEt. The usual work-up afforded 361 mg (100%) of 3-(4-methoxy-2-thienyl)acrylic acid.
The synthesis of compound 8b was performed according to the same procedure as that for 8a: 2-Thienylacryloyl A-Ring Pyrrole Duocarmycin (10a) To a solution of 60% NaH (4.7 mg, 0.12 mmol) in N,N-dimethylformamide (DMF) (0.3 ml) was added a DMF solution (0.4 ml) of 9 (Seg-A) (25 mg, 0.097 mmol), and the mixture was stirred under Ar atmosphere at Ϫ20°C for 2 h 30 min. A solution of 8a (30.7 mg, 0.112 mmol) in DMF (0.4 ml) was added, and the mixture was stirred at Ϫ20°C for 1 h 40 min. Phosphoric buffer (0.01 M, pH 7) was added, and the whole was extracted with AcOEt, and worked up as usual. The residue was purified by column chromatography (CHCl 3 -MeOH, 100 : 1) to give 28 mg (73%) N, 6.38. Found: C, 60.25; H, 4.76; N, 5.76 .
2-Thienylacryloyl 8-O-[(N-Methylpiperazinyl)carbonyl]
A-Ring Pyrrole Duocarmycin B2 Hydrochloride (11a) To a solution of 10a (26.6 mg, 0.0674 mmol) in CH 3 CN (1.32 ml) was added 48% HBr (0.015 ml), and the mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure. p-Nitrophenyl chloroformate (40.8 mg, 0.202 mmol) and triethylamine (0.038 ml, 0.270 mmol) were added to a residue in dry CH 2 Cl 2 (1.32 ml) and toluene (0.53 ml) at Ϫ78°C. Then, the mixture was stirred at Ϫ78°C for 65 min. N-methypiperazine (0.0262 ml, 0.236 mmol) was added to the solution, and the mixture was stirred at 0°C for 1 h 25 min. The mixture was diluted with CHCl 3 , and the combine was washed with aqueous NaHCO 3 , and worked up as usual. The residue was purified by PTLC (CHCl 3 -MeOH, 9 : 1) to give 31.6 mg (78%) of the free base of 11a:
1 
1-Methyl-4-[1؆-methyl-4؆-[1ٟ-methyl-4ٟ-[(tert-butoxycarbonyl)-amino]-2ٟ-pyrrolecarboxyamido]-2؆-pyrrolecarboxamido]-2-pyrrolecarboxy A-Ring Pyrrole Duocarmycin (14b)
Hydrobromic acid in MeOH (5%, 875 mg, 0.541 mmol) was added to a solution of 14a (26.0 mg, 0.0541 mmol) in ClCH 2 CH 2 Cl (2 ml), and the mixture was stirred at 50°C for 4 h. Saturated NaHCO 3 was added, and the whole was extracted with CHCl 3 . The usual work-up afforded 21.6 mg of 15. Compound 12e was added to a solution of 15 (21.6 mg, 0.0541 mmol), DECP (0.0123 ml, 0.0812 mmol) and Et 3 N (0.0226 ml, 0.0162 mmol) in THF (1.3 ml), and the mixture was stirred at room temperature at 0°C for 16 h. Phosphoric buffer (0.01 M, pH 7) was added, the whole was extracted with AcOEt, then worked up as usual. The residue was purified by PTLC (CHCl 3 -MeOH, 12 : 1) to give 17.5 mg (45%) 2.38 (1H, dd, Jϭ7.3, 3.3 Hz), 1.38 (1H, dd, Jϭ4.6, 4 .0 Hz); IR (KBr) 1701, 1684, 1653, 1647, 1578, 1560, 1437, 1381, 1309, 1257, 1109 H, 4.15; N, 15.18. Found: C, 52.50; H, 4.55; N, 14.11 .
1-Methyl-4-[1؆-methyl-4؆-[1ٟ-methyl-4ٟ-[(tert-butoxycarbonyl)amino]-2ٟ-pyrrolecarboxyamido]-2؆-pyrrolecarboxamido]-2-pyrrolecarboxy 8-
O-Acetate A-Ring Pyrrole Duocarmycin B2 (16) Hydrobromic acid in MeOH (5%, 117 mg, 0.0723 mmol) was added to a solution of 14b (17.5 mg, 0.0241 mmol) in CH 3 CN (1.19 ml), and the mixture was stirred at room temperature for 60 min. Then, the reaction mixture was concentrated under reduced pressure. To a solution of the residue in dry CH 2 Cl 2 (1.19 ml) were added Ac 2 O (0.0070 ml, 0.075 mmol) and DMAP (9.41 mg, 0.0771 mmol), and the mixture was stirred at 0°C for 2 h and 10 min. Phosphoric buffer (0.01 M, pH 7) was added, then the whole was extracted with CHCl 3 and worked up as usual. 1697, 1641, 1587, 1541, 1489, 1443, 1404, 1367, 1252, 1205, 1190, The synthesis of compounds 17b and 17c was performed according to the same procedure as that for 17a. (9H, s) ; 2 ml) , and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. To a solution of the residue in DMF (2 ml) was added 17b (72.2 mg, 0.186 mmol) and EDCI (88.9 mg, 0.465 mmol), and the mixture was stirred at room temperature for 17 h and 30 min. Phosphoric buffer (0.01 M, pH 7) was added, then the whole was extracted with AcOEt and worked up as usual. The residue was purified by PTLC (CHCl 3 -MeOH, 10 : 1) to give 32 mg (31%) of 19b: mp 180-190°C (dec.); 1 H-NMR (270 MHz, CDCl 3 ϩCD 3 OD) d: 8.74 (1H, br s), 7.69 (1H, s), 7.58 (1H, d, Jϭ14.9 Hz), 7.31 (1H, br s), 7.18 (1H, s), 6.75 (1H, s), 6.67 (1H, s), 6.55 (1H, s), 6.52 (1H, d, Jϭ15.5 Hz), 4.30 (1H, d, Jϭ15.5 Hz), br), 4.14 (1H, dd, Jϭ10.2, 8.9 Hz), 3.83 (3H, s), m), 3.80 (3H, s), 3.63 (3H, s), 3.19 (1H, dd, Jϭ10.6, 10.2 Hz) , 2.59 (3H, s), 1.41 (9H, s); IR (KBr) 1657, 1635, 1585, 1489, 1446, 1404, 1367, 1296, 1248, 1161 O · 0.3 CHCl 3 : C, 55.63; H, 5.51; N, 11.69. Found: C, 55.52; H, 5.38; N, 1H, s), 6.42 (1H, d, Jϭ14.8 Hz), m), 4.24 (1H, d, Jϭ10.9 Hz), m), 3.86 (3H, s), 3.83 (6H, br s), br), 3.18 (1H, dd, Jϭ10.2 19 (1H, d, Jϭ10.9 Hz), 4.13 (1H, dd, Jϭ10.9, 4.3 Hz), 3.81 (3H, s), 3.67 (3H, s), m), 2.61 (3H, s), 2.35 (1H, dd, Jϭ7.4, 3.5 Hz), 1.50 (9H, s), 1.28 (1H, dd, Jϭ4.9, 3.6 Hz) ; IR (KBr) 1701, 1684, 1653, 1616, 1608, 1576, 1387, 1290, 1244, 1219, H, 5.53; N, 10.11. Found: C, 59.32; H, 5.84; N, 10.25 .
1-Methyl-4-[1؆-methyl-4؆-[(tert-butoxycarbonyl)amino]-2؆-pyrrolecarboxyamido]-2-pyrrolylacryloyl A-Ring Pyrrole Duocarmycin (20b)
A solution of 19b (12.6 mg, 0.0194 mmol) in CH 3 CN (1.1 ml) and pyridine (0.5 ml) was treated with DBU (0.0145 ml, 0.0970 mmol), and the mixture was stirred at room temperature for 2 h and 40 min. Phosphoric buffer (0.01 M, pH 7) was added, then the whole was extracted with CHCl 3 and worked up as usual. The residue was purified by PTLC (CHCl 3 -MeOH, 10 : 1) to give 8.4 mg (69%) H, 5.27; N, 12.00. Found: C, 57.98; H, 5.59; N, O · 0.6 CHCl 3 : C, 56.59; H, 5.35; N, 13.33. Found: C, 56.93; H, 5.49; N, 12.78 .
1-Methyl-4-[(tert-butoxycarbonyl)amino]-2-pyrrolylacryloyl 8-Acetate A-Ring Pyrrole Duocarmycin B2 (21a) Hydrobromic acid in MeOH (5%, 63.8 mg, 0.0394 mmol) was added to a solution of 20a (10 mg, 0.0197 mmol) in CH 2 Cl 2 (0.6 ml), and the mixture was stirred at Ϫ20°C for 20 min. Then, Ac 2 O (0.0056 ml, 0.059 mmol) and DMAP (7.2 mg, 0.059 mmol) were added to the reaction mixture. After stirring at Ϫ20°C for 45 min, phosphoric buffer (0.01 M, pH 7) was added, the whole was extracted with CHCl 3 , and worked up as usual. The reside was purified by PTLC (CHCl 3 , 5.22; N, 12.48. Found: C, 55.87; H, 5.38; N, 11.97 .
1-Methyl-4-[(tert-butoxycarbonyl)amino]-2-pyrrolylacryloyl 8-O-[(N-Methylpiperazinyl)carbonyl] A-Ring Pyrrole Duocarmycin B2 (22)
Hydrobromic acid in MeOH (5%, 160 mg, 0.0988 mmol) was added to a solution of 20a (25.0 mg, 0.0494 mmol) in CH 2 Cl 2 (1.25 ml), and the mixture was stirred at Ϫ20°C for 20 min. The reaction mixture was treated with p-nitrophenyl chloroformate (29.9 mg, 0.148 mmol) and Et 3 N (0.0207 ml, 0.148 mmol), then the mixture was stirred at Ϫ78°C for 20 min. Next, Nmethypiperazine (0.0192 ml, 0.173 mmol) was added, and the mixture was stirred at 0°C for 30 min. The mixture was diluted with CHCl 3 , and washed with aqueous NaHCO 3 . After the usual work-up, the residue was purified by PTLC (CHCl 12 : 1) Interaction of 14b, 20c and 1h with Calf Thymus DNA The interaction of the duocarmycin derivatives with calf thymus DNA were examined by chromatography on a UNISIL pack 5C18 reversed-phase HPLC column (GL Science Co., Ltd., Tokyo, Japan). Calf thymus DNA from Sigma (16.1 mg) was dissolved in 0.01 M phosphate buffer (pH 7, 50 ml). The test compounds were dissolved in DMF to give 6.10ϫ10 Ϫ4 M drug concentration. To this drug solution (9 ml) was added the buffer solution (1 ml) containing calf thymus DNA (or no DNA as the control), and the mixture was kept at 35°C. Samples were collected at intervals and injected directly into the HPLC injection port. The compound was eluted with 0.05 M phosphate buffer (pH 5.9)-acetonitrile (30 : 70) and detected by measuring the absorbance at 330 nm.
Biological Studies Human uterine cervix carcinoma HeLa S 3 cells were obtained from the American Type Culture Collection through Dainippon Pharmaceutical Co. (Osaka, Japan). The cells (2ϫ10 4 /well) were precultured in the culture medium in 24-well multidishes (Nunc, Roskilde, Denmark) for 24 h at 37°C in a humidified atmosphere of 5% CO 2 . For the pulse exposure experiment, cells were treated with each compound for 1 h, washed with Dulbecco's phosphate-buffered saline [Ca 2ϩ -and Mg 2ϩ -free, PBS(Ϫ)], and further incubated in fresh medium for 71 h. For the continuous exposure experiment, cells were treated with each compound for 72 h. Then, cells were treated with PBS(Ϫ) containing 0.05% trypsin (Difco Laboratories, Detroit, MI) and 0.02% EDTA (Wako Pure Chemical Industries Co., Ltd., Osaka, Japan) and counted using a Microcell Counter (CC-180A, Toa Medical Electronics Co., Ltd., Kobe, Japan). The IC 50 values (drug concentration required for 50% inhibition of the cell growth) were determined.
Sarcoma 180 cells were kindly supplied by the National Cancer Center (Tokyo, Japan). Sarcoma 180 cells were passaged and used for the experiment in adult male ddY mice. Murine solid tumor was inoculated subcutaneously (s.c.) at the axillary region of mice. Drugs were administered intravenously (i. according to the method of the National Cancer Institute. 25) The criteria for effectiveness against murine solid tumors was the percentage T/C values with 42% and less, and statistical significance was determined by the Mann-Whitney U test (pϽ0.05). Drug efficacy against human xenografts was expressed as the percentage of mean V/V 0 value against that of the control group, where V is the tumor volume on the day of evaluation and V 0 is the tumor volume on the day of initial drug treatment. The criteria for effectiveness was T/C values of 50% and less, and statistical significance was determined by the Mann-Whitney U test (pϽ0.01, one-sided). 26) Hematotoxicity (Effect of Compounds on Peripheral Blood (PB) Platelet Counts and White Blood Cell Counts) Effect on PB Platelet Counts: Each drug was dissolved with saline and was administered into the tail vein of normal male ddY mice (mean weight 20Ϯ1 g). After 7 d, peripheral blood was obtained from the orbital vein to measure the platelet counts using a microcell counter (CC-180A, Toa Medical Electronics Co., Ltd., Kobe, Japan). Results are presented as the percentage of the absolute value of the treated group versus that of the control (percent of control).
Effect on PB White Blood Cell Counts: Drugs were administered intravenously (i.v.) beginning 1 d after tumor inoculation. After 4 d, peripheral blood was obtained from the orbital vein of tumor-bearing mice to measure the white blood cell counts using a microcell counter (CC-180A, Toa Medical Electronics Co., Ltd., Kobe, Japan). Results are presented as a percentage of the absolute value of the treated group versus that of the control (percent of control).
